Michaël Sébag
- Hematology top 1%
- Multiple Myeloma Research and Treatments 84
- Oncology top 5%
- Peptidase Inhibition and Analysis 23
- Cancer Treatment and Pharmacology 22
- CAR-T cell therapy research 10
- Bone health and treatments 8
- Molecular Biology top 10%
- Protein Degradation and Inhibitors 49
- Ophthalmology top 5%
-
- Monoclonal and Polyclonal Antibodies Research 8
-
- Chronic Lymphocytic Leukemia Research 7
- Co-authors
- Richard KremerDavid GoltzmanJ. S. RhimJanet E. HendersonNizar J. BahlisMarta ChesiP. Leif BergsagelA. Keith Stewart
- Cited by
- HematologyOncologyMolecular Biology
- Journals
- Blood (35 papers)Journal of Clinical Oncology (11 papers)Journal of Medicinal Chemistry (5 papers)
- Partner nations
- CanadaUnited StatesUnited Kingdom
In The Last Decade
Michaël Sébag
103 papers receiving 1.8k citations
Peers
Comparison fields: 5 of 96
- Hematology 801
- Oncology 766
- Molecular Biology 1.0k
- Ophthalmology 113
- Radiology, Nuclear Medicine and Imaging 255
Countries citing papers authored by Michaël Sébag
This map shows the geographic impact of Michaël Sébag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michaël Sébag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michaël Sébag more than expected).
Fields of papers citing papers by Michaël Sébag
This network shows the impact of papers produced by Michaël Sébag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michaël Sébag. The network helps show where Michaël Sébag may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Michaël Sébag, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 2 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 6 | |
| 6 | 2023 | 76 | |
| 7 | 2023 | 1 | |
| 8 | 2023 | 1 | |
| 9 | 2023 | 1 | |
| 10 | 2023 | 9 | |
| 11 | 2019 | 59 | |
| 12 | 2019 | 10 | |
| 13 | 2017 | 4 | |
| 14 | 2017 | 0 | |
| 15 | 2017 | 2 | |
| 16 | 2017 | 3 | |
| 17 | 2017 | 0 | |
| 18 | 2011 | 5 | |
| 19 | 2008 | 54 | |
| 20 | Photodynamic Therapy of Choroidal Neovascularisation Secondary to Traumatic Choroidal Rupture in Young Patients | 2004 | 3 |
About Michaël Sébag
Michaël Sébag is a scholar working on Hematology, Oncology, Molecular Biology, Genetics and Ophthalmology, having authored 115 papers that have together received 1.8k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (84 papers), Protein Degradation and Inhibitors (49 papers), Peptidase Inhibition and Analysis (23 papers), Cancer Treatment and Pharmacology (22 papers), CAR-T cell therapy research (10 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), Bone health and treatments (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). The work is most often cited by research in Hematology (801 citations), Oncology (766 citations), Molecular Biology (1.0k citations), Ophthalmology (113 citations) and Radiology, Nuclear Medicine and Imaging (255 citations). Michaël Sébag has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Richard Kremer, David Goltzman, J. S. Rhim, Janet E. Henderson, Nizar J. Bahlis, Marta Chesi, P. Leif Bergsagel, A. Keith Stewart, Wee Joo Chng and Rafaël Fonseca. Their work appears in journals such as Blood, Journal of Clinical Oncology, Journal of Medicinal Chemistry, HemaSphere and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.